Journal of Autoimmunity · 2024 · 50 citations · 68 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyImmunopathologyInflammationAutoimmune DiseasesChronic InflammationFatigueImmune DysfunctionImmune-mediated DiseaseT Cell ExhaustionExhaustion MarkersImmunological BiomarkersLong CovidLymphocyte ExhaustionPersistent SymptomsPro-inflammatory ChemokinesT Cell Exhaustion BiomarkersT Helper Cell Exhaustion
A substantial number of patients recovering from acute SARS-CoV-2 infection present serious lingering symptoms, often referred to as long COVID (LC). However, a subset of these patients exhibits the most debilitating symptoms characterized by ongoing myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). We specifically identified and studied ME/CFS patients from two independent LC cohorts, at least 12 months post the onset of acute disease, and compared them to the recovered group (R). ME/CFS patients had relatively increased neutrophils and monocytes but reduced lymphocytes. Selective T cell exhaustion with reduced naïve but increased terminal effector T cells was observed in these patients. LC was associated with elevated levels of plasma pro-inflammatory cytokines, chemokines, Galectin-9 (Gal-9), and artemin (ARTN). A defined threshold of Gal-9 and ARTN concentrations had a strong association with LC. The expansion of immunosuppressive CD71+ erythroid cells (CECs) was noted. These cells may modulate the immune response and contribute to increased ARTN concentration, which correlated with pain and cognitive impairment. Serology revealed an elevation in a variety of autoantibodies in LC. Intriguingly, we found that the frequency of 2B4+CD160+ and TIM3+CD160+ CD8+ T cells completely separated LC patients from the R group. Our further analyses using a multiple regression model revealed that the elevated frequency/levels of CD4 terminal effector, ARTN, CEC, Gal-9, CD8 terminal effector, and MCP1 but lower frequency/levels of TGF-β and MAIT cells can distinguish LC from the R group. Our findings provide a new paradigm in the pathogenesis of ME/CFS to identify strategies for its prevention and treatment.
68
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Chen Zhu, Ana C. Anderson, Anna Schubart et al. · Nature Immunology · 2005 · 2K citations